CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

CRSP •

HealthcareBiotechnologyRNA and Genome Editing Developers

AboutCRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its proprietary Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19 positive malignancies; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and pursues various in vivo gene-editing programs that target the liver, lung, muscle, and central nervous system diseases. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.Show more

Revenue $4M -90.0%
EBITDA -$665M -48.6%
Net Income -$582M -58.8%
EPS (Diluted) -6.47 -49.1%
Gross Margin -2642.25% -1129.0%
EBITDA Margin -18933.65% -1381.5%
Operating Margin -18933.65% -1320.3%
Net Margin -16569.77% -1483.5%
ROE -30.18% -57.2%
ROIC -27.4% -40.5%
Debt/Equity 0.11 -7.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.3%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.4%

5Y37.31%

3Y100.42%

TTM-81.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-97.53%

ROCE

10Y Avg-18.96%

5Y Avg-14.93%

3Y Avg-21.15%

Latest-31.12%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	5.16M	41M	3.12M	289.59M	719K	913.08M	436K	370M	35M	3.51M
Revenue Growth %	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%	-89.97%
Cost of Goods Sold+	42.24M	69.8M	113.77M	179.36M	269.41M	101.18M	110.25M	130.25M	110.25M	96.25M
COGS % of Revenue	817.93%	170.26%	3641.9%	61.94%	37469.68%	11.08%	25286.7%	35.2%	315%	2742.25%
Gross Profit+	-37.07M	-28.8M	-110.65M	110.23M	-268.69M	811.9M	-109.81M	239.75M	-75.25M	-92.74M
Gross Margin %	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%	-2642.25%
Gross Profit Growth %	-200.78%	22.31%	-284.16%	199.62%	-343.76%	402.17%	-113.53%	318.32%	-131.39%	-23.25%
Operating Expenses+	73.29M	105.64M	162.07M	63.49M	85.75M	438.38M	563.35M	462.29M	391.32M	571.83M
OpEx % of Revenue	1419.33%	257.69%	5187.8%	21.92%	11925.87%	48.01%	129208.03%	124.94%	1118.05%	16291.4%
Selling, General & Admin	31.06M	35.84M	48.29M	63.49M	85.75M	99.69M	102.46M	76.16M	72.98M	73.54M
SG&A % of Revenue	601.39%	87.43%	1545.9%	21.92%	11925.87%	10.92%	23500.92%	20.58%	208.51%	2095.21%
Research & Development	42.24M	69.8M	113.77M	179.36M	221.38M	340.57M	461.64M	387.33M	320.65M	284.81M
R&D % of Revenue	817.93%	170.26%	3641.9%	61.94%	30790.26%	37.3%	105881.88%	104.68%	916.15%	8114.13%
Other Operating Expenses	78.51M	-197K	-5.49M	-179.36M	-221.38M	-1.88M	-762K	-1.21M	-2.31M	213.48M
Operating Income+	-68.13M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M	-664.57M
Operating Margin %	-1319.33%	-157.69%	-5087.8%	16.14%	-49295.55%	40.91%	-154394.72%	-60.15%	-1333.05%	-18933.65%
Operating Income Growth %	-164.8%	5.11%	-145.86%	129.41%	-858.31%	205.39%	-280.22%	66.94%	-109.66%	-42.44%
EBITDA+	-67.13M	-61.62M	-155.42M	51.47M	-345.25M	391.48M	-648.99M	-202.7M	-447.31M	-664.57M
EBITDA Margin %	-1299.96%	-150.31%	-4975.16%	17.77%	-48018.22%	42.87%	-148850.69%	-54.78%	-1278.02%	-18933.65%
EBITDA Growth %	-162.21%	8.2%	-152.21%	133.11%	-770.85%	213.39%	-265.78%	68.77%	-120.67%	-48.57%
D&A (Non-Cash Add-back)	1M	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M	0
EBIT	-14.67M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M	0
Net Interest Income+	-8.05M	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	-	0	0	0	0	0	0
Interest Expense	8.05M	0	0	-	0	0	0	0	0	0
Other Income/Expense	45.41M	-1.96M	-5.49M	20.57M	6.38M	6M	22.66M	71.82M	103.9M	86.61M
Pretax Income+	-22.72M	-66.61M	-164.43M	67.31M	-348.06M	379.53M	-650.5M	-150.72M	-362.67M	-577.97M
Pretax Margin %	-439.93%	-162.47%	-5263.38%	23.24%	-48408.34%	41.57%	-149197.25%	-40.74%	-1036.19%	-16466.24%
Income Tax+	484K	1.75M	553K	448K	809K	1.87M	-325K	2.89M	3.59M	-3.63M
Effective Tax Rate %	102.13%	102.63%	100.34%	99.33%	100.23%	99.51%	99.95%	101.92%	100.99%	100.63%
Net Income+	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	-581.6M
Net Margin %	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%	-16569.77%
Net Income Growth %	10.17%	-194.62%	-141.35%	140.52%	-621.8%	208.25%	-272.16%	76.37%	-138.43%	-58.8%
Net Income (Continuing)	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.89	-1.71	-3.44	1.17	-5.29	4.70	-8.36	-1.94	-4.34	-6.47
EPS Growth %	-114.77%	9.52%	-101.17%	134.01%	-552.14%	188.85%	-277.87%	76.79%	-123.71%	-49.08%
EPS (Basic)	-1.89	-1.71	-3.44	1.23	-5.29	4.97	-8.36	-1.94	-4.34	-6.47
Diluted Shares Outstanding	12.26M	40.06M	47.96M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M	89.93M
Basic Shares Outstanding	12.26M	39.97M	47.96M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M	89.93M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	320.19M	248.38M	466.39M	987.55M	1.72B	2.42B	1.85B	1.91B	1.94B	1.99B
Cash & Short-Term Investments	315.52M	239.76M	456.65M	943.77M	1.69B	2.38B	1.82B	1.69B	1.9B	1.98B
Cash Only	315.52M	239.76M	456.65M	943.77M	1.17B	923.03M	211.88M	389.48M	298.26M	347.56M
Short-Term Investments	0	0	0	0	521.71M	1.46B	1.6B	1.3B	1.61B	1.63B
Accounts Receivable	3.16M	2.63M	88K	99K	10.84M	305K	0	200M	25M	0
Days Sales Outstanding	223.14	23.38	10.28	0.12	5.5K	0.12	-	197.3	260.71	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.51M	6M	9.66M	0	0	8.4M	11.7M	6.5M	8.31M	9.84M
Total Non-Current Assets+	24.77M	22.96M	22.62M	79.2M	111.35M	334.36M	390.03M	321.49M	304.9M	279.57M
Property, Plant & Equipment	21.03M	18.86M	18.5M	72.83M	93.03M	312.04M	320.56M	305.94M	277.55M	247.57M
Fixed Asset Turnover	0.25x	2.17x	0.17x	3.98x	0.01x	2.93x	0.00x	1.21x	0.13x	0.01x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	399K	344K	289K	235K	180K	125K	71K	16K	0	0
Long-Term Investments	3.15M	3.15M	3.16M	5.04M	0	0	53.13M	1.97M	0	0
Other Non-Current Assets	3.35M	3.76M	3.83M	6.14M	18.14M	22.2M	16.27M	13.57M	27.35M	32M
Total Assets+	344.96M	271.35M	489.02M	1.07B	1.83B	2.75B	2.24B	2.23B	2.24B	2.27B
Asset Turnover	0.01x	0.15x	0.01x	0.27x	0.00x	0.33x	0.00x	0.17x	0.02x	0.00x
Asset Growth %	116.38%	-21.34%	80.22%	118.14%	71.36%	50.54%	-18.49%	-0.6%	0.56%	1.04%
Total Current Liabilities+	22M	14.51M	27.75M	57.11M	94.26M	119.88M	121.11M	108.79M	87.78M	149.12M
Accounts Payable	4.57M	1.64M	5.07M	5.94M	9.09M	14.82M	27.43M	38.15M	14.71M	11.14M
Days Payables Outstanding	39.48	8.57	16.26	12.1	12.32	53.45	90.8	106.9	48.7	42.24
Short-Term Debt	0	0	0	8.49M	11.36M	12.16M	15.84M	15.63M	17.29M	18.58M
Deferred Revenue (Current)	0	0	0	960K	2.34M	1.01M	0	4.11M	3.85M	15.77M
Other Current Liabilities	14.82M	6.97M	14.95M	25.9M	38.59M	67.51M	58.46M	33.13M	33.05M	114.77M
Current Ratio	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x	13.32x
Quick Ratio	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x	13.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	90.12M	69M	69.08M	70.22M	69.47M	232.53M	246.47M	237.98M	222.17M	194.31M
Long-Term Debt	0	0	0	0	0	0	0	0	0	188.17M
Capital Lease Obligations	0	0	0	44.05M	50.07M	212.87M	228.18M	223.01M	206.41M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.47M	12.07M	11.29M	14.39M	7.63M	7.34M	5.97M	958K	3.44M	6.14M
Total Liabilities	112.12M	83.51M	96.82M	127.33M	163.73M	352.42M	367.58M	346.77M	309.95M	343.43M
Total Debt+	0	0	0	52.54M	61.43M	225.03M	244.02M	238.63M	223.69M	206.75M
Net Debt	-315.52M	-239.76M	-456.65M	-891.23M	-1.11B	-698M	32.14M	-150.84M	-74.56M	-140.81M
Debt / Equity	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x	0.11x
Debt / EBITDA	-	-	-	1.02x	-	0.57x	-	-	-	-
Net Debt / EBITDA	-	-	-	-17.32x	-	-1.78x	-	-	-	-
Interest Coverage	-8.46x	-	-	-	-	-	-	-	-	-
Total Equity+	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B	1.92B
Equity Growth %	899.5%	-19.33%	108.8%	139.53%	77.15%	44.18%	-21.84%	0.39%	2.62%	-0.53%
Book Value per Share	19.00	4.69	8.18	16.50	25.23	29.85	24.12	23.77	22.90	21.37
Total Shareholders' Equity	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B	1.92B
Common Stock	1.22M	1.24M	1.58M	1.85M	2.28M	2.39M	2.44M	2.5M	2.7M	3.09M
Retained Earnings	-57.08M	-125.44M	-291.57M	-224.71M	-573.58M	-195.91M	-846.09M	-999.7M	-1.37B	-1.95B
Treasury Stock	0	0	-57K	-63K	-63K	-63K	-63K	-62K	-62K	0
Accumulated OCI	-26K	14K	-8K	7K	-83K	-5.07M	-15.65M	1.91M	1.84M	4.82M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-55.31M	-70.1M	-96.24M	56.68M	-238.37M	538.97M	-495.74M	-260.38M	-142.77M	-345.01M
Operating CF Margin %	-1071.07%	-170.98%	-3080.63%	19.57%	-33152.43%	59.03%	-113702.06%	-70.37%	-407.93%	-9829.46%
Operating CF Growth %	-193.07%	-26.73%	-37.29%	158.89%	-520.57%	326.11%	-191.98%	47.48%	45.17%	-141.65%
Net Income	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	-581.6M
Depreciation & Amortization	925K	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M	19.48M
Stock-Based Compensation	10.84M	18.87M	34.98M	44.06M	66.02M	102.39M	97.95M	81.03M	86.57M	72.5M
Deferred Taxes	-53.71M	0	4.28M	0	0	0	0	0	0	0
Other Non-Cash Items	8.05M	1.75M	15.41M	-10.53M	1.86M	14.11M	12.47M	-14.04M	-38.62M	144.61M
Working Capital Changes	1.78M	-25.39M	10.55M	-48.43M	33.44M	26.86M	19.84M	-193.59M	156.27M	0
Change in Receivables	-2.82M	531K	2.54M	-11K	-45K	-161K	305K	-200M	175M	25M
Change in Inventory	-1.09M	-551.3M	332.3M	0	-25.75M	-37.51M	0	0	0	0
Change in Payables	3.86M	546.62M	-323.28M	0	25.75M	37.51M	5.16M	-20.25M	0	44.89M
Cash from Investing+	31.88M	-8.31M	-2.77M	1.32M	-541.17M	-1.04B	-258.65M	374.65M	-280.48M	-31.8M
Capital Expenditures	-3.02M	-7.81M	-2.77M	-6.68M	-18.36M	-81.7M	-37.19M	-9.47M	-1.9M	-914K
CapEx % of Revenue	58.4%	19.06%	88.76%	2.31%	2553.27%	8.95%	8529.36%	2.56%	5.43%	26.04%
Acquisitions	-100K	0	0	0	522.81M	953.73M	221.47M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	35M	-500K	0	8.01M	-522.81M	-953.73M	-221.47M	-2.5M	0	-34M
Cash from Financing+	183.22M	2.61M	315.93M	430.98M	1.02B	250.94M	38.59M	62.66M	331.98M	426.03M
Debt Issued (Net)	35.01M	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	1000K	1000K	970K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	-57K	0	0	0	0	0	0	71.25M
Other Financing	-1.78M	2.61M	8.94M	15.96M	33.86M	37.68M	37.62M	0	31.29M	426.03M
Net Change in Cash	159.56M	-75.76M	216.9M	489M	236.66M	-245.52M	-715.88M	177.59M	-91.29M	49.3M
Free Cash Flow+	-58.33M	-77.91M	-99.01M	49.99M	-256.72M	457.27M	-532.93M	-269.85M	-144.68M	-345.93M
FCF Margin %	-1129.47%	-190.04%	-3169.4%	17.26%	-35705.7%	50.08%	-122231.42%	-72.93%	-413.36%	-9855.5%
FCF Growth %	-200.09%	-33.58%	-27.08%	150.49%	-613.52%	278.12%	-216.55%	49.37%	46.39%	-139.11%
FCF per Share	-4.76	-1.94	-2.06	0.88	-3.89	5.69	-6.85	-3.41	-1.71	-3.85
FCF Conversion (FCF/Net Income)	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x	0.59x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-22.78%	-32.5%	-56.89%	10.04%	-26.8%	18.59%	-30.42%	-8.17%	-19.2%	-30.18%
Return on Invested Capital (ROIC)	-	-	-	72.74%	-87.84%	24.81%	-27.98%	-9.17%	-19.5%	-27.4%
Gross Margin	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%	-2642.25%
Net Margin	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%	-16569.77%
Debt / Equity	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x	0.11x
Interest Coverage	-8.46x	-	-	-	-	-	-	-	-	-
FCF Conversion	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x	0.59x
Revenue Growth	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%	-89.97%

US Stock Screener

...

CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

CRSP •

HealthcareBiotechnologyRNA and Genome Editing Developers

Revenue $4M -90.0%
EBITDA -$665M -48.6%
Net Income -$582M -58.8%
EPS (Diluted) -6.47 -49.1%
Gross Margin -2642.25% -1129.0%
EBITDA Margin -18933.65% -1381.5%
Operating Margin -18933.65% -1320.3%
Net Margin -16569.77% -1483.5%
ROE -30.18% -57.2%
ROIC -27.4% -40.5%
Debt/Equity 0.11 -7.1%
Interest Coverage -

Technical Analysis

Key Insights

Based on financial data analysis

✓Strengths

✓Strong 5Y sales CAGR of 37.3%

✗Weaknesses

✗Weak Piotroski F-Score: 2/9
✗Negative free cash flow
✗Low asset turnover indicates capital-intensive operations

Price & Volume

Loading chart...

Growth Metrics

Revenue CAGR

10Y30.4%

5Y37.31%

3Y100.42%

TTM-81.72%

Profit (Net Income) CAGR

10Y-

5Y-

3Y-

TTM-103.8%

EPS CAGR

10Y-

5Y-

3Y-

TTM-97.53%

ROCE

10Y Avg-18.96%

5Y Avg-14.93%

3Y Avg-21.15%

Latest-31.12%

Peer Comparison

RNA and Genome Editing Developers

Name	Market Cap	Current Price	P/E Ratio	Revenue Growth 1Y	Net Margin	ROE	FCF Yield	Debt/Equity
ALNYAlnylam Pharmaceuticals, Inc.	44.07B	332.92	142.88	65.19%	8.45%	39.76%	1.06%	3.76
SLXNWSilexion Therapeutics Ltd.	63.6M	0.03	0.00			-132.54%
EDITEditas Medicine, Inc.	205.18M	2.20	-0.76	-58.64%	-430.84%	-14.85%		0.26
SGMOSangamo Therapeutics, Inc.	92.01M	0.43	-0.88	-67.2%	-331.28%	-17.44%		1.34
CAMPCAMP4 Therapeutics Corporation	210.49M	4.49	-1.69	86.29%	-14.04%	-133.54%		0.14
SLNSilence Therapeutics plc	256.95M	5.44	-1.71	70.47%	-252.16%	-84.61%		0.00
PEPGPepGen Inc.	202.89M	6.22	-2.18			-57.35%		0.16
ARCTArcturus Therapeutics Holdings Inc.	224.14M	8.23	-2.74	-12.27%	-72.48%	-29.71%		0.12

Profit & Loss

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Sales/Revenue+	5.16M	41M	3.12M	289.59M	719K	913.08M	436K	370M	35M	3.51M
Revenue Growth %	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%	-89.97%
Cost of Goods Sold+	42.24M	69.8M	113.77M	179.36M	269.41M	101.18M	110.25M	130.25M	110.25M	96.25M
COGS % of Revenue	817.93%	170.26%	3641.9%	61.94%	37469.68%	11.08%	25286.7%	35.2%	315%	2742.25%
Gross Profit+	-37.07M	-28.8M	-110.65M	110.23M	-268.69M	811.9M	-109.81M	239.75M	-75.25M	-92.74M
Gross Margin %	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%	-2642.25%
Gross Profit Growth %	-200.78%	22.31%	-284.16%	199.62%	-343.76%	402.17%	-113.53%	318.32%	-131.39%	-23.25%
Operating Expenses+	73.29M	105.64M	162.07M	63.49M	85.75M	438.38M	563.35M	462.29M	391.32M	571.83M
OpEx % of Revenue	1419.33%	257.69%	5187.8%	21.92%	11925.87%	48.01%	129208.03%	124.94%	1118.05%	16291.4%
Selling, General & Admin	31.06M	35.84M	48.29M	63.49M	85.75M	99.69M	102.46M	76.16M	72.98M	73.54M
SG&A % of Revenue	601.39%	87.43%	1545.9%	21.92%	11925.87%	10.92%	23500.92%	20.58%	208.51%	2095.21%
Research & Development	42.24M	69.8M	113.77M	179.36M	221.38M	340.57M	461.64M	387.33M	320.65M	284.81M
R&D % of Revenue	817.93%	170.26%	3641.9%	61.94%	30790.26%	37.3%	105881.88%	104.68%	916.15%	8114.13%
Other Operating Expenses	78.51M	-197K	-5.49M	-179.36M	-221.38M	-1.88M	-762K	-1.21M	-2.31M	213.48M
Operating Income+	-68.13M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M	-664.57M
Operating Margin %	-1319.33%	-157.69%	-5087.8%	16.14%	-49295.55%	40.91%	-154394.72%	-60.15%	-1333.05%	-18933.65%
Operating Income Growth %	-164.8%	5.11%	-145.86%	129.41%	-858.31%	205.39%	-280.22%	66.94%	-109.66%	-42.44%
EBITDA+	-67.13M	-61.62M	-155.42M	51.47M	-345.25M	391.48M	-648.99M	-202.7M	-447.31M	-664.57M
EBITDA Margin %	-1299.96%	-150.31%	-4975.16%	17.77%	-48018.22%	42.87%	-148850.69%	-54.78%	-1278.02%	-18933.65%
EBITDA Growth %	-162.21%	8.2%	-152.21%	133.11%	-770.85%	213.39%	-265.78%	68.77%	-120.67%	-48.57%
D&A (Non-Cash Add-back)	1M	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M	0
EBIT	-14.67M	-64.65M	-158.94M	46.74M	-354.44M	373.53M	-673.16M	-222.54M	-466.57M	0
Net Interest Income+	-8.05M	0	0	0	0	0	0	0	0	0
Interest Income	0	0	0	-	0	0	0	0	0	0
Interest Expense	8.05M	0	0	-	0	0	0	0	0	0
Other Income/Expense	45.41M	-1.96M	-5.49M	20.57M	6.38M	6M	22.66M	71.82M	103.9M	86.61M
Pretax Income+	-22.72M	-66.61M	-164.43M	67.31M	-348.06M	379.53M	-650.5M	-150.72M	-362.67M	-577.97M
Pretax Margin %	-439.93%	-162.47%	-5263.38%	23.24%	-48408.34%	41.57%	-149197.25%	-40.74%	-1036.19%	-16466.24%
Income Tax+	484K	1.75M	553K	448K	809K	1.87M	-325K	2.89M	3.59M	-3.63M
Effective Tax Rate %	102.13%	102.63%	100.34%	99.33%	100.23%	99.51%	99.95%	101.92%	100.99%	100.63%
Net Income+	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	-581.6M
Net Margin %	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%	-16569.77%
Net Income Growth %	10.17%	-194.62%	-141.35%	140.52%	-621.8%	208.25%	-272.16%	76.37%	-138.43%	-58.8%
Net Income (Continuing)	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	0
Discontinued Operations	0	0	0	0	0	0	0	0	0	0
Minority Interest	0	0	0	0	0	0	0	0	0	0
EPS (Diluted)+	-1.89	-1.71	-3.44	1.17	-5.29	4.70	-8.36	-1.94	-4.34	-6.47
EPS Growth %	-114.77%	9.52%	-101.17%	134.01%	-552.14%	188.85%	-277.87%	76.79%	-123.71%	-49.08%
EPS (Basic)	-1.89	-1.71	-3.44	1.23	-5.29	4.97	-8.36	-1.94	-4.34	-6.47
Diluted Shares Outstanding	12.26M	40.06M	47.96M	56.93M	65.95M	80.39M	77.75M	79.22M	84.36M	89.93M
Basic Shares Outstanding	12.26M	39.97M	47.96M	54.39M	65.95M	75.95M	77.75M	79.22M	84.36M	89.93M
Dividend Payout Ratio	-	-	-	-	-	-	-	-	-	-

Balance Sheet

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Total Current Assets+	320.19M	248.38M	466.39M	987.55M	1.72B	2.42B	1.85B	1.91B	1.94B	1.99B
Cash & Short-Term Investments	315.52M	239.76M	456.65M	943.77M	1.69B	2.38B	1.82B	1.69B	1.9B	1.98B
Cash Only	315.52M	239.76M	456.65M	943.77M	1.17B	923.03M	211.88M	389.48M	298.26M	347.56M
Short-Term Investments	0	0	0	0	521.71M	1.46B	1.6B	1.3B	1.61B	1.63B
Accounts Receivable	3.16M	2.63M	88K	99K	10.84M	305K	0	200M	25M	0
Days Sales Outstanding	223.14	23.38	10.28	0.12	5.5K	0.12	-	197.3	260.71	-
Inventory	0	0	0	0	0	0	0	0	0	0
Days Inventory Outstanding	-	-	-	-	-	-	-	-	-	-
Other Current Assets	1.51M	6M	9.66M	0	0	8.4M	11.7M	6.5M	8.31M	9.84M
Total Non-Current Assets+	24.77M	22.96M	22.62M	79.2M	111.35M	334.36M	390.03M	321.49M	304.9M	279.57M
Property, Plant & Equipment	21.03M	18.86M	18.5M	72.83M	93.03M	312.04M	320.56M	305.94M	277.55M	247.57M
Fixed Asset Turnover	0.25x	2.17x	0.17x	3.98x	0.01x	2.93x	0.00x	1.21x	0.13x	0.01x
Goodwill	0	0	0	0	0	0	0	0	0	0
Intangible Assets	399K	344K	289K	235K	180K	125K	71K	16K	0	0
Long-Term Investments	3.15M	3.15M	3.16M	5.04M	0	0	53.13M	1.97M	0	0
Other Non-Current Assets	3.35M	3.76M	3.83M	6.14M	18.14M	22.2M	16.27M	13.57M	27.35M	32M
Total Assets+	344.96M	271.35M	489.02M	1.07B	1.83B	2.75B	2.24B	2.23B	2.24B	2.27B
Asset Turnover	0.01x	0.15x	0.01x	0.27x	0.00x	0.33x	0.00x	0.17x	0.02x	0.00x
Asset Growth %	116.38%	-21.34%	80.22%	118.14%	71.36%	50.54%	-18.49%	-0.6%	0.56%	1.04%
Total Current Liabilities+	22M	14.51M	27.75M	57.11M	94.26M	119.88M	121.11M	108.79M	87.78M	149.12M
Accounts Payable	4.57M	1.64M	5.07M	5.94M	9.09M	14.82M	27.43M	38.15M	14.71M	11.14M
Days Payables Outstanding	39.48	8.57	16.26	12.1	12.32	53.45	90.8	106.9	48.7	42.24
Short-Term Debt	0	0	0	8.49M	11.36M	12.16M	15.84M	15.63M	17.29M	18.58M
Deferred Revenue (Current)	0	0	0	960K	2.34M	1.01M	0	4.11M	3.85M	15.77M
Other Current Liabilities	14.82M	6.97M	14.95M	25.9M	38.59M	67.51M	58.46M	33.13M	33.05M	114.77M
Current Ratio	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x	13.32x
Quick Ratio	14.56x	17.12x	16.81x	17.29x	18.21x	20.17x	15.30x	17.54x	22.07x	13.32x
Cash Conversion Cycle	-	-	-	-	-	-	-	-	-	-
Total Non-Current Liabilities+	90.12M	69M	69.08M	70.22M	69.47M	232.53M	246.47M	237.98M	222.17M	194.31M
Long-Term Debt	0	0	0	0	0	0	0	0	0	188.17M
Capital Lease Obligations	0	0	0	44.05M	50.07M	212.87M	228.18M	223.01M	206.41M	0
Deferred Tax Liabilities	0	0	0	0	0	0	0	0	0	0
Other Non-Current Liabilities	12.47M	12.07M	11.29M	14.39M	7.63M	7.34M	5.97M	958K	3.44M	6.14M
Total Liabilities	112.12M	83.51M	96.82M	127.33M	163.73M	352.42M	367.58M	346.77M	309.95M	343.43M
Total Debt+	0	0	0	52.54M	61.43M	225.03M	244.02M	238.63M	223.69M	206.75M
Net Debt	-315.52M	-239.76M	-456.65M	-891.23M	-1.11B	-698M	32.14M	-150.84M	-74.56M	-140.81M
Debt / Equity	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x	0.11x
Debt / EBITDA	-	-	-	1.02x	-	0.57x	-	-	-	-
Net Debt / EBITDA	-	-	-	-17.32x	-	-1.78x	-	-	-	-
Interest Coverage	-8.46x	-	-	-	-	-	-	-	-	-
Total Equity+	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B	1.92B
Equity Growth %	899.5%	-19.33%	108.8%	139.53%	77.15%	44.18%	-21.84%	0.39%	2.62%	-0.53%
Book Value per Share	19.00	4.69	8.18	16.50	25.23	29.85	24.12	23.77	22.90	21.37
Total Shareholders' Equity	232.85M	187.83M	392.19M	939.42M	1.66B	2.4B	1.88B	1.88B	1.93B	1.92B
Common Stock	1.22M	1.24M	1.58M	1.85M	2.28M	2.39M	2.44M	2.5M	2.7M	3.09M
Retained Earnings	-57.08M	-125.44M	-291.57M	-224.71M	-573.58M	-195.91M	-846.09M	-999.7M	-1.37B	-1.95B
Treasury Stock	0	0	-57K	-63K	-63K	-63K	-63K	-62K	-62K	0
Accumulated OCI	-26K	14K	-8K	7K	-83K	-5.07M	-15.65M	1.91M	1.84M	4.82M
Minority Interest	0	0	0	0	0	0	0	0	0	0

Cash Flow

	Dec 2016	Dec 2017	Dec 2018	Dec 2019	Dec 2020	Dec 2021	Dec 2022	Dec 2023	Dec 2024	Dec 2025
Cash from Operations+	-55.31M	-70.1M	-96.24M	56.68M	-238.37M	538.97M	-495.74M	-260.38M	-142.77M	-345.01M
Operating CF Margin %	-1071.07%	-170.98%	-3080.63%	19.57%	-33152.43%	59.03%	-113702.06%	-70.37%	-407.93%	-9829.46%
Operating CF Growth %	-193.07%	-26.73%	-37.29%	158.89%	-520.57%	326.11%	-191.98%	47.48%	45.17%	-141.65%
Net Income	-23.2M	-68.36M	-164.98M	66.86M	-348.87M	377.66M	-650.17M	-153.61M	-366.25M	-581.6M
Depreciation & Amortization	925K	3.02M	3.52M	4.72M	9.18M	17.95M	24.17M	19.84M	19.26M	19.48M
Stock-Based Compensation	10.84M	18.87M	34.98M	44.06M	66.02M	102.39M	97.95M	81.03M	86.57M	72.5M
Deferred Taxes	-53.71M	0	4.28M	0	0	0	0	0	0	0
Other Non-Cash Items	8.05M	1.75M	15.41M	-10.53M	1.86M	14.11M	12.47M	-14.04M	-38.62M	144.61M
Working Capital Changes	1.78M	-25.39M	10.55M	-48.43M	33.44M	26.86M	19.84M	-193.59M	156.27M	0
Change in Receivables	-2.82M	531K	2.54M	-11K	-45K	-161K	305K	-200M	175M	25M
Change in Inventory	-1.09M	-551.3M	332.3M	0	-25.75M	-37.51M	0	0	0	0
Change in Payables	3.86M	546.62M	-323.28M	0	25.75M	37.51M	5.16M	-20.25M	0	44.89M
Cash from Investing+	31.88M	-8.31M	-2.77M	1.32M	-541.17M	-1.04B	-258.65M	374.65M	-280.48M	-31.8M
Capital Expenditures	-3.02M	-7.81M	-2.77M	-6.68M	-18.36M	-81.7M	-37.19M	-9.47M	-1.9M	-914K
CapEx % of Revenue	58.4%	19.06%	88.76%	2.31%	2553.27%	8.95%	8529.36%	2.56%	5.43%	26.04%
Acquisitions	-100K	0	0	0	522.81M	953.73M	221.47M	0	0	0
Investments	-	-	-	-	-	-	-	-	-	-
Other Investing	35M	-500K	0	8.01M	-522.81M	-953.73M	-221.47M	-2.5M	0	-34M
Cash from Financing+	183.22M	2.61M	315.93M	430.98M	1.02B	250.94M	38.59M	62.66M	331.98M	426.03M
Debt Issued (Net)	35.01M	0	0	0	0	0	0	0	0	0
Equity Issued (Net)	1000K	0	1000K	1000K	1000K	1000K	970K	1000K	1000K	0
Dividends Paid	0	0	0	0	0	0	0	0	0	0
Share Repurchases	0	0	-57K	0	0	0	0	0	0	71.25M
Other Financing	-1.78M	2.61M	8.94M	15.96M	33.86M	37.68M	37.62M	0	31.29M	426.03M
Net Change in Cash	159.56M	-75.76M	216.9M	489M	236.66M	-245.52M	-715.88M	177.59M	-91.29M	49.3M
Free Cash Flow+	-58.33M	-77.91M	-99.01M	49.99M	-256.72M	457.27M	-532.93M	-269.85M	-144.68M	-345.93M
FCF Margin %	-1129.47%	-190.04%	-3169.4%	17.26%	-35705.7%	50.08%	-122231.42%	-72.93%	-413.36%	-9855.5%
FCF Growth %	-200.09%	-33.58%	-27.08%	150.49%	-613.52%	278.12%	-216.55%	49.37%	46.39%	-139.11%
FCF per Share	-4.76	-1.94	-2.06	0.88	-3.89	5.69	-6.85	-3.41	-1.71	-3.85
FCF Conversion (FCF/Net Income)	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x	0.59x
Interest Paid	0	0	0	0	0	0	0	0	0	0
Taxes Paid	0	0	0	0	0	0	0	0	0	0

Key Ratios

Metric	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025
Return on Equity (ROE)	-22.78%	-32.5%	-56.89%	10.04%	-26.8%	18.59%	-30.42%	-8.17%	-19.2%	-30.18%
Return on Invested Capital (ROIC)	-	-	-	72.74%	-87.84%	24.81%	-27.98%	-9.17%	-19.5%	-27.4%
Gross Margin	-717.93%	-70.26%	-3541.9%	38.06%	-37369.68%	88.92%	-25186.7%	64.8%	-215%	-2642.25%
Net Margin	-449.3%	-166.74%	-5281.08%	23.09%	-48520.86%	41.36%	-149122.71%	-41.52%	-1046.43%	-16569.77%
Debt / Equity	-	-	-	0.06x	0.04x	0.09x	0.13x	0.13x	0.12x	0.11x
Interest Coverage	-8.46x	-	-	-	-	-	-	-	-	-
FCF Conversion	2.38x	1.03x	0.58x	0.85x	0.68x	1.43x	0.76x	1.70x	0.39x	0.59x
Revenue Growth	1990.69%	693.9%	-92.38%	9169.85%	-99.75%	126893.18%	-99.95%	84762.39%	-90.54%	-89.97%

CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CRSP vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios

CRISPR Therapeutics AG (CRSP) 10-Year Financial Performance & Capital Metrics

Key Insights

✓Strengths

✗Weaknesses

Price & Volume

Growth Metrics

Revenue CAGR

Profit (Net Income) CAGR

EPS CAGR

ROCE

Peer Comparison

Compare CRSP vs Peers

vs ALNY

vs IONS

Compare Top 5

Profit & Loss

Balance Sheet

Cash Flow

Key Ratios

Deep Dive Analysis

Valuation Overview

Total Return Calculator

Dividend History

Earnings History

Price History

Revenue History

Financial Ratios